A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Study of AMG510 in Subjects with Advanced Solid Tumors
Sponsor: Amgen
Enrolling: Male and Female Patients
IRB Number: AAAS7409
U.S. Govt. ID: NCT04185883
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to obtain information on the safety and side effects, good or bad, of two new drug combinations; AMG 510 plus trametinib and AMG 510 plus AMG 404. Subjects will participate in one of two research groups. Group A will receive AMG 510 and trametinib. Research Group B will receive AMG 510 and AMG 404. AMG 510 is an anticancer drug that is being developed for tumors with a specific mutation called KRAS p.G12C. AMG 404 is an anticancer drug that works by activating an immune response against the cancer by blocking the activity of a molecule called PD-1. Trametinib is an anticancer drug that interferes with the growth and spread of cancer cells in the body.
This study is closed
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have confirmed locally-advanced or metastatic malignancy? Yes No
Are you able to take oral medications? Yes No
Are you willing to record your daily intake of the study drugs? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator